Wilbanks Smith & Thomas Asset Management LLC Uni Qure N.V. Transaction History

Wilbanks Smith & Thomas Asset Management LLC

$3.54 Billion
Q1 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$29.24 - $42.03 $171,434 - $246,421	-5,863 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$35.35 - $50.67 $449,086 - $643,711	-12,704 Reduced 68.42%	5,863 $212,000
Q3 2020 Nov 12, 2020	BUY	$35.98 - $47.66 $387,828 - $513,727	10,779 Added 138.41%	18,567 $684,000
Q2 2020 Jul 31, 2020	BUY	$45.06 - $67.74 $143,561 - $215,819	3,186 Added 69.23%	7,788 $351,000
Q1 2020 May 06, 2020	BUY	$40.01 - $73.97 $184,126 - $340,409	4,602 New	4,602 $218,000
Q4 2018 Feb 08, 2019	SELL	$22.8 - $33.93 $4,560 - $6,786	-200 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$29.75 - $43.08 $5,950 - $8,616	200 New	200 $7,000

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilbanks Smith & Thomas Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilbanks Smith & Thomas Asset Management LLC with notifications on news.

Account